Dr. Sujit Sheth
Pediatric Hematology & Oncology (Pediatric Hematology & Oncology Physician)
3959 Broadway, Columbia University Department Pediatrics
New York, NY 10032
- Medicare participating
At a glance
- Years since graduation
- 38
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 13
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Hematology & Oncology Physician primary
NY license 206410
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- New York-Presbyterian Hospital New York, NY
Medical groups
- Weill Medical College of Cornell (2,051 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 13
- Services billed
- 140
- Patients’ average age
- 51
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 5 companies reported 52 payments worth $84,313 in total to this clinician.
| Agios Pharmaceuticals, Inc. | $26,644 |
|---|---|
| Vertex Pharmaceuticals Incorporated | $24,754 |
| Chiesi USA, Inc. | $15,681 |
| Celgene Corporation | $11,962 |
| Novo Nordisk Health Care AG | $5,273 |
| Consulting Fee | $49,097 |
|---|---|
| Travel and Lodging | $32,333 |
| Food and Beverage | $2,883 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Celgene Corporation Jun 14, 2025 | Travel and Lodging travel to Milan, Italy | $10,391 |
| Vertex Pharmaceuticals Incorporated Jun 9, 2025 | Travel and Lodging travel to MILAN, Italy · in-kind | $10,173 |
| Chiesi USA, Inc. Dec 23, 2025 | Travel and Lodging FERRIPROX · TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA · travel to LONDON, UK, Great Britain (UK) | $6,374 |
| Novo Nordisk Health Care AG Feb 1, 2025 | Consulting Fee | $5,273 |
| Vertex Pharmaceuticals Incorporated Aug 6, 2025 | Consulting Fee | $5,152 |
| Vertex Pharmaceuticals Incorporated Feb 12, 2025 | Consulting Fee | $4,970 |
| Agios Pharmaceuticals, Inc. Sep 26, 2025 | Consulting Fee PYRUKYND · Genetically Defined Disease | $3,605 |
| Vertex Pharmaceuticals Incorporated Jun 11, 2025 | Consulting Fee | $2,925 |
| Agios Pharmaceuticals, Inc. Jul 23, 2025 | Consulting Fee PYRUKYND · Genetically Defined Disease | $2,775 |
| Chiesi USA, Inc. Nov 13, 2025 | Consulting Fee FERRIPROX · TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | $2,610 |
All 38 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Chiesi USA, Inc. Dec 23, 2025 | Travel and Lodging FERRIPROX · TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA · travel to LONDON, UK, Great Britain (UK) | $6,374 |
| Chiesi USA, Inc. Dec 11, 2025 | Consulting Fee FERRIPROX · TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | $2,610 |
| Agios Pharmaceuticals, Inc. Dec 10, 2025 | Consulting Fee PYRUKYND · Genetically Defined Disease | $2,450 |
| Agios Pharmaceuticals, Inc. Dec 8, 2025 | Consulting Fee PYRUKYND · Genetically Defined Disease | $85.38 |
| Chiesi USA, Inc. Nov 13, 2025 | Consulting Fee FERRIPROX · TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | $2,610 |
| Chiesi USA, Inc. Nov 13, 2025 | Consulting Fee FERRIPROX · TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | $1,740 |
| Chiesi USA, Inc. Nov 13, 2025 | Consulting Fee FERRIPROX · TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | $582 |
| Chiesi USA, Inc. Nov 13, 2025 | Travel and Lodging FERRIPROX · TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA · travel to LONDON, Great Britain (UK) | $307 |
| Agios Pharmaceuticals, Inc. Nov 13, 2025 | Travel and Lodging PYRUKYND · Genetically Defined Disease · travel to London, Great Britain (UK) | $307 |
| Agios Pharmaceuticals, Inc. Nov 12, 2025 | Consulting Fee PYRUKYND · Genetically Defined Disease | $307 |
| Agios Pharmaceuticals, Inc. Sep 30, 2025 | Travel and Lodging PYRUKYND · Genetically Defined Disease · travel to London, Great Britain (UK) Company’s description2 nights accommodation | $582 |
| Agios Pharmaceuticals, Inc. Sep 26, 2025 | Consulting Fee PYRUKYND · Genetically Defined Disease | $3,605 |
| Agios Pharmaceuticals, Inc. Sep 26, 2025 | Travel and Lodging PYRUKYND · Genetically Defined Disease · travel to Garden City, NY | $799 |
| Agios Pharmaceuticals, Inc. Sep 26, 2025 | Consulting Fee PYRUKYND · Genetically Defined Disease | $278 |
| Vertex Pharmaceuticals Incorporated Aug 6, 2025 | Consulting Fee | $5,152 |
| Agios Pharmaceuticals, Inc. Jul 23, 2025 | Consulting Fee PYRUKYND · Genetically Defined Disease | $2,775 |
| Chiesi USA, Inc. Jul 10, 2025 | Consulting Fee FERRIPROX · TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | $858 |
| Chiesi USA, Inc. Jul 10, 2025 | Travel and Lodging FERRIPROX · TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA · travel to MILAN, Italy | $440 |
| Agios Pharmaceuticals, Inc. Jul 3, 2025 | Consulting Fee PYRUKYND · Genetically Defined Disease | $555 |
| Agios Pharmaceuticals, Inc. Jul 2, 2025 | Consulting Fee PYRUKYND · Genetically Defined Disease | $1,778 |
| Agios Pharmaceuticals, Inc. Jul 2, 2025 | Consulting Fee PYRUKYND · Genetically Defined Disease | $1,110 |
| Agios Pharmaceuticals, Inc. Jun 20, 2025 | Consulting Fee PYRUKYND · Genetically Defined Disease | $1,665 |
| Agios Pharmaceuticals, Inc. Jun 19, 2025 | Consulting Fee PYRUKYND · Genetically Defined Disease | $2,495 |
| Celgene Corporation Jun 14, 2025 | Travel and Lodging travel to Milan, Italy | $10,391 |
| Celgene Corporation Jun 14, 2025 | Travel and Lodging travel to Milan, Italy | $786 |
| Celgene Corporation Jun 13, 2025 | Travel and Lodging travel to Milan, Italy | $786 |
| Vertex Pharmaceuticals Incorporated Jun 12, 2025 | Travel and Lodging travel to MILAN, Italy · in-kind | $657 |
| Vertex Pharmaceuticals Incorporated Jun 11, 2025 | Consulting Fee | $2,925 |
| Vertex Pharmaceuticals Incorporated Jun 9, 2025 | Travel and Lodging travel to MILAN, Italy · in-kind | $10,173 |
| Agios Pharmaceuticals, Inc. May 30, 2025 | Consulting Fee PYRUKYND · Genetically Defined Disease | $1,943 |
| Agios Pharmaceuticals, Inc. Mar 15, 2025 | Consulting Fee PYRUKYND · Genetically Defined Disease | $1,110 |
| Agios Pharmaceuticals, Inc. Feb 17, 2025 | Consulting Fee PYRUKYND · Genetically Defined Disease | $1,110 |
| Agios Pharmaceuticals, Inc. Feb 17, 2025 | Consulting Fee PYRUKYND · Genetically Defined Disease | $1,110 |
| Vertex Pharmaceuticals Incorporated Feb 12, 2025 | Consulting Fee | $4,970 |
| Vertex Pharmaceuticals Incorporated Feb 12, 2025 | Travel and Lodging travel to SAN DIEGO, CA · in-kind | $300 |
| Vertex Pharmaceuticals Incorporated Feb 12, 2025 | Travel and Lodging travel to SAN DIEGO, CA · in-kind | $268 |
| Vertex Pharmaceuticals Incorporated Feb 12, 2025 | Travel and Lodging travel to SAN DIEGO, CA · in-kind | $164 |
| Novo Nordisk Health Care AG Feb 1, 2025 | Consulting Fee | $5,273 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $70,823 in research payments for these studies, mostly to the institutions running them.
- A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06421636 - Study name not reported
Agios Pharmaceuticals, Inc. - Study name not reported
Agios Pharmaceuticals, Inc. - Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT04143724 - Study name not reported
Agios Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.